Senior Manager, Corporate Development & Strategic Analytics jobs in United States
cer-icon
Apply on Employer Site
company-logo

REGENXBIO · 1 day ago

Senior Manager, Corporate Development & Strategic Analytics

REGENXBIO is an exceptional place to work, aiming to bring core values of Trust, Accountability, Perseverance, and Innovation to life. The Senior Manager, Corporate Development & Strategic Analytics will support business development, licensing, M&A, and competitive intelligence activities through strategic modeling and financial analysis, contributing to long-range planning and deal execution.

BiopharmaBiotechnologyGeneticsTherapeutics

Responsibilities

Assist and maintain comprehensive three statement model detailing long range plan (LRP) and SOTP analysis identifying key drivers of value across product portfolio, future programs and sublicenses
Assist with strategic financial modeling exercises (both bona fide and theoretical), ranging in complexity from bespoke program NPVs to three statement merger models; insights inform and underpin strategic decision making
At an organizational level, employ and maintain consistent valuation approaches including general discounting conventions and risk adjustment
Create modeling tools to drive efficiency for different functions
Support recurring / ad-hoc competitive intelligence analyses and data harvesting
Support execution of transactions to build REGENXBIO’s portfolio and technologies
Support identification and prioritization of new business opportunities as well partnering efforts with respect to REGENXBIO existing assets
Support and conduct cross functional due diligence in coordination with other functions including R&D, clinical, manufacturing, and commercial
Support generation of analyses and executive ready materials in connection with all opportunities setting forth strategic rationale therefor
Assist and perform post deal integration and certain alliance management activities
It is imperative that REGENXBIO employees embody our core values by working collaboratively, building strong relationships and using clear communication to meet shared objectives

Qualification

Financial modelingValuation analysisBiotechnology industry experienceM&A transactionsMicrosoft Office proficiencyCapital IQEvaluate PharmaCitelineVDR softwareAnalytical skillsInterpersonal skillsCommunication skillsOrganizational skillsProblem-solving skillsAdaptabilityCollaboration

Required

Bachelor's Degree with a concentration in finance or scientific discipline required
+5 years investment banking, private equity or equity research experience at bulge bracket institution or biotechnology corporate development required
Advanced, extensive financial, valuation and strategic modeling experience spanning transactions ranging in complexity from licensing to M&A
Experience or general familiarity with biotechnology industry sourcing, evaluation, coordination and execution of strategic transactions
General understanding of the underlying science, clinical development, as well as the business components of product development
Skill in prioritizing and triaging obligations; ability to independently manage a wide range of projects and relationships
Detail-oriented, ability to handle pressure and meet deadlines
Outstanding organizational, analytical, interpersonal and communication skills
Ability to deliver executive-ready presentation with minimal oversight and guidance
Adaptability, flexibility, and willingness to work in a changing environment
A collaborative nature with the knowledge and understanding of the role and importance of working cross-functionally
Self-starter, highly motivated, results-driven individual; ability to creatively solve problems
Expert facility and understanding of the Microsoft Office, Capital IQ, Evaluate Pharma, Citeline, VDR software / platforms

Preferred

Master's Degree (MBA, or similar) preferred

Benefits

Annual bonus program
Education assistance
Retirement plan with employer match
Stock options at all levels
Summer hours

Company

REGENXBIO

twittertwittertwitter
company-logo
REGENXBIO develops adeno-associated viral vector-based therapeutics and research tools, offering NAV, a recombinant AAV-vector.

Funding

Current Stage
Public Company
Total Funding
$928.19M
Key Investors
Vivo Capital
2025-05-19Post Ipo Debt· $150M
2024-03-06Post Ipo Equity· $140M
2021-01-06Post Ipo Equity· $230.3M

Leadership Team

leader-logo
Curran Simpson
President and CEO
linkedin
leader-logo
Francesca Cook
Vice President, Global Pricing and Market Access
linkedin
Company data provided by crunchbase